Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

by Ballestrero, A., Benelli, M., Bergqvist, M., Bernardo, A., Bliss, J.M, Bonetti, A., Breast International Group and PYTHIA Collaborators, Cameron, D., Colleoni, M., Davies, D.M, De Swert, H., Duhoux, F.P, Fumagalli, D., Gebhart, G., Henry, S., Hilbers, F.S, Ignatiadis, M., International Breast Cancer Study Group, Jerusalem, G., Kammler, R., Loi, S., MacPherson, I.R, Maibach, R., Malorni, L., McCartney, A., Migliaccio, I., Neven, P., Papadimitriou, K., Piccart, M., Regan, M.M, Ruepp, B., Seles, E., Thomson, A., Tyekucheva, S., Zoppoli, G.
Published 2022

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer

by Hays, E., Le, V., Narsipur, N., Rosario, K., Tran, D.K, Wilson, L., Zhong, L.
Published 2021

SpikChIP: A novel computational methodology to compare multiple ChIP-seq using spike-in chromatin

by Aranda, S., Blanco, E., Di Croce, L.
Published 2021